Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.84 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.67 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.67 |
| ▸ | BRD4 | O60885 | 2/20 | 0.65 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.65 |
| ▸ | BRD2 | P25440 | 1/20 | 0.65 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794576 | 0.99 | MAPK14 (0.85) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL6961441 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL6961445 | 0.91 | MAPK14 (1.00) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL6952550 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL6581980 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13CSNK1DMAPK12MAPK11 | |
| SCHEMBL6957344 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL21797188 | 0.87 | MAPK14 (0.82) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL6576577 | 0.86 | MAPK14 (0.91) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL6578983 | 0.86 | MAPK14 (0.91) | MAPK14MAPK13EGFRCSNK1DCSNK1E | |
| SCHEMBL6578912 | 0.86 | MAPK14 (0.91) | MAPK14MAPK13EGFRCSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730683-B2 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2004-05-04 | — | — | US | claimed |
| US-20020198206-A1 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2002-12-26 | — | — | US | claimed |
| US-6730683-B2 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2004-05-04 | — | — | US | disclosed |
| US-20020198206-A1 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | SMITHKLINE BEECHAM CORPORATION | 2002-12-26 | — | — | US | disclosed |
| US-6335340-B1 | REACTING POLYMER BOUND 2-THIOPYRIMIDINE-4-YL IMINE WITH AN ISONITRILE; OXIDATION TO SULFONE OR SULFOXIDE TO RELEASE; AMINATION; ADMINISTERING AS CYTOKINE, INTERLEUKIN, AND TUMOR NECROSIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198206-A1 | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses | IL2, IFNG, IL2RA | MAPK14 1513/4885MAPK13 1208/4885EGFR 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.